Eli Lilly and Co has finally received approval from the USA's FDA, and there will be a two-horse race in the field of Alzheimer's disease.

Eli Lilly and Co executives wrote that Kisunla has shown a very meaningful effect, and patients urgently need this effective treatment plan.

cls.cn08:46

Biogen Shares Are Trading Lower After the FDA Approved Competitor Eli Lilly's Kisunla for Early Symptomatic Alzheimer's Disease. Pharma Stocks Fell Earlier in the Session After President Biden and Senator Sanders Called on Some Companies to Lower Drug...

Biogen Shares Are Trading Lower After the FDA Approved Competitor Eli Lilly's Kisunla for Early Symptomatic Alzheimer's Disease. Pharma Stocks Fell Earlier in the Session After President Biden and Sen

Benzinga02:02

Express News | US pharmaceutical company Biogen fell 2.8% to an intraday low, after Eli Lilly and Co (LLY.N) announced a delay in the FDA approval of its Alzheimer's drug.

Breakings01:55

Eli Lilly Wins FDA Approval of Donanemab for Alzheimer's

Seeking Alpha01:54

Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth

Yahoo Finance00:45

Express News | Biogen Completes Acquisition of Human Immunology Biosciences

BreakingsJul 2 21:16